Tag:

Foundation Medicine

Latest Headlines

Latest Headlines

Foundation Medicine will develop a test for Clovis' ovarian cancer drug

Foundation Medicine will develop a companion diagnostic test for use with a Clovis Oncology drug now in mid-stage clinical trials to treat patients with ovarian cancer.

Foundation Medicine teams up with Clovis Oncology to develop ovarian cancer Dx

Foundation Medicine recently revealed plans to raise up to $150 million in a secondary offering to fuel R&D and announced on Thursday that it is teaming up with Clovis Oncology to develop an innovative companion diagnostic for ovarian cancer.

Foundation Medicine seeks up to $150M to keep its cancer Dx growth engine running

Cancer diagnostics wunderkind Foundation Medicine has revealed plans to raise as much as $150 million in a secondary offering to fuel domestic and international expansion and the development of new products to keep the growth engine running.

Foundation Medicine's Q4 propelled a 10%-plus stock price hike

Investors drove Foundation Medicine's stock up more than 10% during late morning trading on Feb. 26. What got them moving? They responded to news that the cancer diagnostic darling continued to grow revenue at a healthy clip as 2013 came to a close.

Foundation Medicine teams up with Novartis for cancer diagnostics

The recently IPO'd Foundation Medicine has expanded its relationship with Novartis, lending out its gene-profiling technology to help the drugmaker develop cancer treatments.

Foundation Medicine deepens its Novartis ties with new deal

Diagnostics luminary Foundation Medicine has expanded its relationship with pharma giant Novartis, giving the drugmaker more access to its gene profiling technology to develop cancer treatments.

Foundation Medicine shows test's worth as a highly specific blood cancer screening tool

Foundation Medicine is touting some promising new data highlighting the utility of its signature diagnostic technology for blood cancers, news that will help the newly public Massachusetts startup maintain development and commercial momentum.

Foundation Medicine's Dx revenue grows rapidly in Q3

Cancer diagnostics darling Foundation Medicine released its first quarterly numbers as a public company, and they show encouraging revenue gains as the Massachusetts outfit pursued a rapid sales expansion for its debut product.

The top 10 biotech IPOs of 2013

Last year when we did the list of the top 10 biotech IPOs of 2012, we were lucky to have 10. Actually, there were 11, and that looked pretty good compared to the lean and hungry years of 2008 to...

Are medical device companies invited to the biotech IPO party?

Despite renewed investor fervor and no shortage of promising technologies, medical device outfits had so far been largely loathe to join in on the biotech IPO revival. Now that LDR has bagged an over-allotted, top-of-its range debut, is it time for med tech's big moment?